National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

lobradimil
A synthetic analog of bradykinin. Lobradimil is a potent, specific bradykinin B-2 receptor agonist that stimulates B-2 receptors expressed on the surface of brain capillary endothelial cells, thereby reversibly increasing the permeability of the blood-brain barrier (BBB). Compared to bradykinin, this agent possesses enhanced receptor selectivity, greater plasma stability, and a longer half-life. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:RMP-7
US brand name:Cereport
Code name:DRG-0182
Chemical structure names:
  • L-Prolinamide, L-Arginyl-L-prolyl-trans-4- hydroxy-L-prolyl-3-(2- thienyl)-L-alanylglycl -L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1- -carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-, (S-(R*,R*))
  • L-Prolinamide,L-Arginyl-L-protyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-02-004-0(aminoiminomethyl)amino)-1-0(4-methoxyphenyl)methyl)ethyl)-,0S-(R*,R*))



Previous:live-attenuated Listeria encoding human mesothelin vaccine CRS-207, LMB-1 immunotoxin, LMB-2 immunotoxin, LMB-7 immunotoxin, LMB-9 immunotoxin
Next:Lodine, lometrexol, lomustine, lonafarnib, loperamide hydrochloride

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov